India-based global pharma company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL.

Brivaracetam is the bioequivalent to UCB Inc's Briviact Oral Solution, 10 mg/mL and is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.

Following the FDA approval, Lupin has commenced the launch of Brivaracetam Oral Solution in the United States.